News
The year 2025 was a period of intensive development and consistent strengthening of Biostat Research and Development Center’s position at the intersection of research, technology, and healthcare. New clients and projects in the areas of clinical, observational, and marketing research, the dynamic development of Medfile software and the HaloDoctor telemedicine platform, the implementation of AI-based solutions, and an approximately 10% increase in employment — this briefly sums up the past twelve months.
We begin the summary of 2025 with another significant distinction. For the seventh consecutive year, Biostat was awarded the status of a Research and Development Centre by the Polish Minister of Development and Technology. In 2025, only 61 companies nationwide held this title, confirming Biostat’s strong and stable position among Poland’s most innovative enterprises.
In 2025, Biostat continued its cooperation with leading pharmaceutical and medical companies, including Adamed, AstraZeneca, Celon Pharma, Chiesi, Ipsen, Polpharma, Takeda, MSD, and QVITI S.A. The projects covered a broad range of therapeutic areas such as cardiology, oncology, transplantology, neonatology, gastroenterology, allergology, and surgery.
Among the most notable ongoing and completed projects were studies on generalized myasthenia gravis, newborns with respiratory distress syndrome treated with surfactant, risk factors for glucose metabolism disorders in kidney transplant patients, and a research experiment involving renal artery denervation combined with atrial fibrillation ablation in patients with heart failure. Studies in rare diseases were also conducted, including adrenocortical carcinoma.
At the same time, Biostat prepared a PASS (Post Authorisation Safety Study) concerning the use of human fibrinogen and human thrombin in pediatric surgical patients — the project is currently awaiting a decision from the EMA. Participation in studies conducted in the United States was also continued, including research on neurostimulation in post-stroke treatment and therapy for patients newly diagnosed with multiple myeloma.
In 2025, Biostat successfully completed, among others, a molecular epidemiological study among adult allergy patients for an international client, a study on oncological immunotherapy using Onko BCG preparations, and a retrospective analysis of patient profiles and treatment regimens in non-small cell lung cancer (NSCLC). A support and monitoring program for post-stroke patients focusing on spasticity was also brought to completion.
The past year also brought cooperation with new partners, including the launch of a medical device study for Orthoget, comparing a hybrid intramedullary nail system with the PRECICE® solution in adult patients with lower limb length discrepancy. Biostat continued to support non-commercial clinical trials conducted for academic and medical institutions such as the Medical University of Warsaw, Wrocław Medical University, Medical University of Gdańsk, National Institute of Oncology, Jagiellonian University, University Clinical Hospital in Opole, Nicolaus Copernicus University in Toruń, Silesian Center for Heart Diseases, and the Institute of Hematology and Transfusion Medicine.
In 2025, Biostat also launched a knowledge portal dedicated to clinical research and significantly expanded its proprietary eTMF system for managing clinical and observational study documentation. The company also completed the EcoVadis certification process, achieving a very high score and preparing for recertification.
The year 2025 was equally intensive in the field of marketing and opinion research. Biostat once again conducted a study for the Anna Dymna “Mimo Wszystko” Foundation on the recognition of the Enchanted Song Festival. Long-standing cooperation continued with brands such as OSM Łowicz, Big Star, Politan, and Smart Lunch, for which comprehensive research supporting business decisions was carried out.
Projects were also completed for RECARO Rail, the Itaka Foundation, Wirtualna Polska (as part of the “Cyfrowi Bezpieczni” initiative), the Croma brand, and the Open Cages (Otwarte Klatki) organization. Key projects included brand awareness and image studies for Bank Gospodarstwa Krajowego, as well as numerous market analyses across the energy, transport, real estate, financial, food, and medical sectors.
An important part of Biostat’s activities involved large-scale research projects for the National Institute of Music and Dance, including nationwide studies of dance audiences and a report on the presence and promotion of the polonaise in Polish schools. Biostat also conducted a survey among participants of the Pyrkon Fantasy Festival 2025, comparing this year’s edition with data from the previous six years.
In 2025, Biostat also carried out employee research and market benchmarks for companies and institutions across various sectors, as well as academic projects related to the labor market, HR analytics, and working conditions, in cooperation with institutions such as the Central Institute for Labour Protection – National Research Institute, the University of Łódź, and the Poznań University of Economics and Business.
The year 2025 was a period of intensive growth for Medfile and the HaloDoctor telemedicine platform. More than 20,000 doctors and medical specialists now use the comprehensive facility management software. Over the past twelve months, the medfile.pl and halodoctor.pl services were visited by a total of 7.2 million unique users.
The development of the Medfile® system focused on user comfort, process automation, and reducing administrative burdens. New AI-based tools were introduced, along with improvements in medical documentation and solutions supporting registration, administration, and facility management.
AI-based implementations included, among others, the AI Voice Assistant, AI Patient Assistant, and AI Teleassistant supporting telephone services. Integration of Medfile® with the Medidesk tool was also completed, significantly improving ticket handling and patient communication.
The Medfile brand was present at the Academy of Healthcare Managers (AMOZ) conference, and a new job portal for doctors and medical staff was launched within the platform.
HaloDoctor.pl also introduced a Health Service featuring articles co-created with doctors and experts.
In 2025, Biostat expanded its publishing activities by launching the Seniorzy.pl and Zwierzaki.info portals. Both platforms are based on expert content related to human and animal health, providing reliable knowledge and practical advice. Seniorzy.pl offers information on healthy lifestyles, legal guidance, and a database of senior care homes, while Zwierzaki.info features an extensive pet adoption section and content focused on animal welfare.
By the end of 2025, Biostat’s team consisted of over 100 specialists — project managers, clinical research associates, software developers, data analysts, statisticians, customer support specialists, journalists, and managers with expertise in AI applications in medicine.
— Year on year, Biostat’s employment increased by approximately 10%. Along with the growing innovativeness of our projects, we significantly strengthened our IT department. The recognition for 2025 belongs to the entire team — the company’s dynamic growth is possible solely thanks to the commitment and expertise of our specialists
Biostat enters 2026 with a clearly defined vision for further development, based on technology, data, and scaling solutions that have proven successful in the Polish market in recent years. A key direction will remain the continued use of artificial intelligence — including machine learning algorithms and large language models (LLMs) — both in research and in healthcare IT solutions.
In the area of clinical and observational research, Biostat plans to further develop tools supporting process automation, data analysis, and research documentation management. AI and machine learning technologies will increasingly support research teams, shorten project timelines, and improve the quality of analyses.
At the same time, the company intends to consistently expand its proprietary technological products. One of the most important goals for the coming months will be scaling Medfile software and telemedicine solutions into additional European markets. Experience gained in Poland — both in working with medical facilities and in serving millions of patients — provides a solid foundation for further expansion.
— Artificial intelligence is not a passing trend for us, but a natural and consistent direction of development for the coming years. We are entering 2026 under the motto “all hands on deck”: full engagement of our teams in developing and implementing AI-, machine learning-, and LLM-based solutions. This is now an absolute priority — in healthcare software, telemedicine, and clinical research alike. At the same time, we are intensively working on scaling our medical software to European markets. Our goal is to create solutions that truly support doctors, medical facilities, and patients, regardless of the country in which they are used
